Rezolute (NASDAQ:RZLT – Get Free Report) and Dynavax Technologies (NASDAQ:DVAX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
83.0% of Rezolute shares are owned by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are owned by institutional investors. 20.8% of Rezolute shares are owned by company insiders. Comparatively, 3.0% of Dynavax Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Rezolute and Dynavax Technologies’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rezolute | N/A | N/A | -$51.79 million | ($1.14) | -3.77 |
| Dynavax Technologies | $232.28 million | 5.93 | -$6.39 million | $0.06 | 175.50 |
Analyst Ratings
This is a summary of recent recommendations for Rezolute and Dynavax Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rezolute | 0 | 0 | 7 | 0 | 3.00 |
| Dynavax Technologies | 0 | 1 | 3 | 0 | 2.75 |
Rezolute presently has a consensus price target of $10.14, suggesting a potential upside of 135.88%. Dynavax Technologies has a consensus price target of $25.33, suggesting a potential upside of 140.58%. Given Dynavax Technologies’ higher probable upside, analysts clearly believe Dynavax Technologies is more favorable than Rezolute.
Profitability
This table compares Rezolute and Dynavax Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rezolute | N/A | -60.90% | -54.58% |
| Dynavax Technologies | 3.91% | 1.52% | 0.95% |
Risk and Volatility
Rezolute has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
Summary
Dynavax Technologies beats Rezolute on 10 of the 13 factors compared between the two stocks.
About Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
